Recent advances in the screening methods of NPC1L1 inhibitors

Renshuai Zhang; Wenjing Liu; Jun Zeng; Jingsen Meng; Lingyu Shi; Shanbo Yang; Jing Chang; Chao Wang; Kunyue Xing; Jialian Wen; Ning Liu; Bing Liang; Dongming Xing

Biomedicine & Pharmacotherapy (Nov 2022)

Recent advances in the screening methods of NPC1L1 inhibitors

Renshuai Zhang,
Wenjing Liu,
Jun Zeng,
Jingsen Meng,
Lingyu Shi,
Shanbo Yang,
Jing Chang,
Chao Wang,
Kunyue Xing,
Jialian Wen,
Ning Liu,
Bing Liang,
Dongming Xing

Affiliations

Renshuai Zhang: Cancer Institute, The Affiliated Hospital of Qingdao University, Qingdao University, School of Basic Medicine of Qingdao University, Qingdao, China; Qingdao Cancer Institute, Qingdao, China
Wenjing Liu: Cancer Institute, The Affiliated Hospital of Qingdao University, Qingdao University, School of Basic Medicine of Qingdao University, Qingdao, China; Qingdao Cancer Institute, Qingdao, China
Jun Zeng: Cancer Institute, The Affiliated Hospital of Qingdao University, Qingdao University, School of Basic Medicine of Qingdao University, Qingdao, China; Qingdao Cancer Institute, Qingdao, China
Jingsen Meng: Cancer Institute, The Affiliated Hospital of Qingdao University, Qingdao University, School of Basic Medicine of Qingdao University, Qingdao, China; Qingdao Cancer Institute, Qingdao, China
Lingyu Shi: Cancer Institute, The Affiliated Hospital of Qingdao University, Qingdao University, School of Basic Medicine of Qingdao University, Qingdao, China; Qingdao Cancer Institute, Qingdao, China
Shanbo Yang: Cancer Institute, The Affiliated Hospital of Qingdao University, Qingdao University, School of Basic Medicine of Qingdao University, Qingdao, China; Qingdao Cancer Institute, Qingdao, China
Jing Chang: Cancer Institute, The Affiliated Hospital of Qingdao University, Qingdao University, School of Basic Medicine of Qingdao University, Qingdao, China; Qingdao Cancer Institute, Qingdao, China
Chao Wang: Cancer Institute, The Affiliated Hospital of Qingdao University, Qingdao University, School of Basic Medicine of Qingdao University, Qingdao, China; Qingdao Cancer Institute, Qingdao, China
Kunyue Xing: Alliance Manchester Business School, The University of Manchester, Manchester, UK
Jialian Wen: School of Social Science, The University of Manchester, Manchester, UK; Corresponding author.
Ning Liu: Cancer Institute, The Affiliated Hospital of Qingdao University, Qingdao University, School of Basic Medicine of Qingdao University, Qingdao, China; Qingdao Cancer Institute, Qingdao, China; Corresponding authors at: Cancer Institute, The Affiliated Hospital of Qingdao University, Qingdao University, School of Basic Medicine of Qingdao University, Qingdao, China
Bing Liang: Cancer Institute, The Affiliated Hospital of Qingdao University, Qingdao University, School of Basic Medicine of Qingdao University, Qingdao, China; Qingdao Cancer Institute, Qingdao, China; Corresponding authors at: Cancer Institute, The Affiliated Hospital of Qingdao University, Qingdao University, School of Basic Medicine of Qingdao University, Qingdao, China
Dongming Xing: Cancer Institute, The Affiliated Hospital of Qingdao University, Qingdao University, School of Basic Medicine of Qingdao University, Qingdao, China; Qingdao Cancer Institute, Qingdao, China; School of Life Sciences, Tsinghua University, Beijing, China; Corresponding authors at: Cancer Institute, The Affiliated Hospital of Qingdao University, Qingdao University, School of Basic Medicine of Qingdao University, Qingdao, China

Journal volume & issue: Vol. 155
p. 113732

Abstract

Read online

NPC1L1 is a crucial protein involved in sterol lipid absorption and has been shown to play an important role in intestinal cholesterol absorption. Hypercholesterolemia is a significant risk factor for cardiovascular diseases such as coronary heart disease. Screening of NPC1L1 inhibitors is critical for gaining a full understanding of lipid metabolism, developing new cholesterol-lowering medicines, and treating cardiovascular diseases. This work summarized existing methodologies for screening NPC1L1 inhibitors and evaluated their challenges, and will assist the development of novel cholesterol-lowering medications and therapeutic strategies for hypercholesterolemia and other cholesterol-related metabolic disorders.

Published in Biomedicine & Pharmacotherapy

ISSN: 0753-3322 (Print); 1950-6007 (Online)
Publisher: Elsevier
Country of publisher: France
LCC subjects: Medicine: Therapeutics. Pharmacology
Website: https://www.journals.elsevier.com/biomedicine-and-pharmacotherapy

About the journal

Abstract

Keywords